

ABSTRACT

An siRNA targeting 17 β -hydroxysteroid dehydrogenase type 13 and a siRNA conjugate. Also disclosed are a pharmaceutical composition, cell or kit containing the siRNA, and a
5 method for using the siRNA for the treatment and/or prevention of subjects suffering from HSD17B13-related disorders (such as chronic fibroinflammatory liver disease).